A combination of viral and participant factors influence virologic outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies

被引：0

作者：

Margolis, D. ^{[1
]}

Schapiro, J. ^{[2
]}

Perno, C. ^{[3
]}

Kuritzkes, D. ^{[4
]}

Quercia, R. ^{[5
]}

Patel, P. ^{[6
]}

Polli, J. ^{[7
]}

Cutrell, A. ^{[8
]}

Dorey, D. ^{[9
]}

Wang, Y. ^{[10
]}

Wu, S. ^{[11
]}

van Eygen, V. ^{[12
]}

Crauwels, H. ^{[12
]}

Ford, S. ^{[13
]}

Baker, M. ^{[14
]}

Talarico, C. ^{[15
]}

St Clair, M. ^{[16
]}

Jeffrey, J. ^{[16
]}

White, C. ^{[17
]}

Vanveggel, S. ^{[12
]}

Van Solingen-Ristea, R. ^{[12
]}

Vandermeulen, K. ^{[12
]}

Spreen, W. ^{[1
]}

van Lunzen, J. ^{[18
]}

机构：

[1] ViiV Healthcare, Clin Dev, Res & Dev, Res Triangle Pk, NC USA

[2] Sheba Med Ctr, HIV AIDS Clin, Natl Hemophilia Ctr, Ramat Gan, Israel

[3] IRCCS Bambino Gesu Pediat Hosp, Expt Med & Surg, Rome, Italy

[4] Harvard Med Sch, Div Infect Dis, Brigham & Womens Hosp, Boston, MA 02115 USA

[5] ViiV Healthcare, Clin Virol, Brentford, England

[6] ViiV Healthcare, Global Med Affairs, Res Triangle Pk, NC USA

[7] ViiV Healthcare, Global Med Sci, Res Triangle Pk, NC USA

[8] ViiV Healthcare, Stat, R&D, Res Triangle Pk, NC USA

[9] GlaxoSmithKline, Stat, R&D, Mississauga, ON, Canada

[10] ViiV Healthcare, Stat, R&D, Collegeville, PA USA

[11] GlaxoSmithKline, Stat, R&D, Collegeville, PA USA

[12] Janssen Res & Dev, Clin R&D, Beerse, Belgium

[13] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Res Triangle Pk, NC USA

[14] ViiV Healthcare, Clin Pharmacol, Nyon, Switzerland

[15] ViiV Healthcare, Translat Med Res, Res Triangle Pk, NC USA

[16] ViiV Healthcare, Clin Virol, Res Triangle Pk, NC USA

[17] ViiV Healthcare, Bioinformat, Res Triangle Pk, NC USA

[18] ViiV Healthcare, Translat Med Res, Munich, Germany

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

O442

引用

页码：15 / 16

页数：2

共 13 条

[1] A combination of viral and participant factors influence virological outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M Phase 3 studies
Patel, Parul
Schapiro, Jonathan
Perno, Carlo
Kuritzkes, Daniel
Cutrell, Amy
Dorey, David
Wang, Yongwei
Van Eygen, Veerle
Crauwels, Herta
Ford, Susan
Talarico, Christine
St Clair, Marty
Jeffrey, Jerry
Vandermeulen, Kati
Spreen, William
Van Lunzen, Jan
HIV MEDICINE, 2021, 22 : 26 - 27
[2] Viral and participant factors influence virologic outcome to CAB plus RPV LA: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M
Margolis, David A.
Schapiro, Jonathan M.
Perno, Carlo Federico
Kuritzkes, Daniel R.
Quercia, Romina
Patel, Parul
Polli, Joseph W.
Cutrell, Amy
Dorey, David
Wang, Yongwei
Wu, Sterling
van Eygen, Veerle
Crauwels, Herta
Ford, Susan
Baker, Mark
Talarico, Christine
St Clair, Marty
Jeffrey, Jerry
White, C. Thomas
Vanveggel, Simon
Van Solingen-Ristea, Rodica
Vandermeulen, Kati
Spreen, William
van Lunzen, Jan
Scherzer, Jenny
INFECTION, 2021, 49 (SUPPL 1) : S6 - S7
[3] Safety profile of cabotegravir plus rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the phase 3 FLAIR, ATLAS, and ATLAS-2M studies
de los Rios, P.
Patel, P.
Huang, J.
Harrington, C.
D'Amico, R.
Thiagarajah, S.
Birmingham, E.
Van Solingen-Ristea, R.
Spreen, W. R.
Baugh, B.
Bosse, M.
HIV MEDICINE, 2021, 22 : 131 - 131
[4] Safety profile of cabotegravir plus rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the Phase 3 FLAIR, ATLAS and ATLAS-2M studies
de los Rios, Patricia
Patel, Parul
Huang, Jenny
Harrington, Conn
D'Amico, Ronald
Thiagarajah, Shanker
Birmingham, Eileen
Van Solingen-Ristea, Rodica
Spreen, William R.
Baugh, Bryan
Benn, Paul D.
Bosse, Matthew
HIV MEDICINE, 2022, 23 : 13 - 13
[5] Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)
Chounta, V.
Wu, S.
Upadhyay, O.
Griffith, S.
Harrington, C.
Orkin, C.
Swindells, S.
Spreen, W.
Margolis, D.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 24 - 24
[6] Patient-reported outcomes after 152 weeks of HIV maintenance therapy with long-acting cabotegravir plus rilpivirine in the phase IIIb ATLAS-2M study
Chounta, V.
Overton, E.
Noe, S.
Swindells, S.
Negredo, E.
D'Amico, R.
Harrington, C.
Vanveggel, S.
Van Solingen-Ristea, R.
Wang, Y.
Acuipil, C.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 72 - 73
[7] Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results
Benn, P.
Quercia, R.
Hudson, K.
Wang, Y.
Chounta, V.
Talarico, C.
Ford, S.
Cutrell, A.
Margolis, D.
Van Solingen-Ristea, R.
Vanveggel, S.
Van Eygen, V.
Polli, J.
de Ruiter, A.
Smith, K.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 28 - 29
[8] Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir plus Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure
Orkin, Chloe
Schapiro, Jonathan M.
Perno, Carlo F.
Kuritzkes, Daniel R.
Patel, Parul
DeMoor, Rebecca
Dorey, David
Wang, Yongwei
Han, Kelong
Van Eygen, Veerle
Crauwels, Herta
Ford, Susan L.
Latham, Christine L.
St. Clair, Marty
Polli, Joseph W.
Vanveggel, Simon
Vandermeulen, Kati
D'Amico, Ronald
Garges, Harmony P.
Zolopa, Andrew
Spreen, William R.
van Wyk, Jean
Cutrell, Amy G.
CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) : 1423 - 1431
[9] Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
Vasiliki Chounta
Edgar T. Overton
Anthony Mills
Susan Swindells
Paul D. Benn
Simon Vanveggel
Rodica van Solingen-Ristea
Yuanyuan Wang
Krischan J. Hudson
Mark S. Shaefer
David A. Margolis
Kimberly Y. Smith
William R. Spreen
The Patient - Patient-Centered Outcomes Research, 2021, 14 : 849 - 862
[10] Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
Chounta, Vasiliki
Overton, Edgar T.
Mills, Anthony
Swindells, Susan
Benn, Paul D.
Vanveggel, Simon
van Solingen-Ristea, Rodica
Wang, Yuanyuan
Hudson, Krischan J.
Shaefer, Mark S.
Margolis, David A.
Smith, Kimberly Y.
Spreen, William R.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (06): : 849 - 862

← 1 2 →